

CLAIMS

1. Use of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat a syndrome or a pathology in which the NR2-B sub-unit of the N-methyl-D-
5 aspartate receptor is involved.

2. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat increased sensitivity and memorisation of pain,
10 and consequently the development of chronic pain.

3. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat tolerance to the analgesic effects of opioid
15 analgesics.

4. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat Alzheimer's disease.

20 5. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat ischemia.

25 6. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat Parkinson's disease.

7. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat Huntington's chorea.

5 8. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat epilepsy.

10 9. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat dementia, including dementia following a viral infection.

15 10. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat manic-depressive psychosis and other split personality syndromes.

20 11. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat dependence on substances with a toxicomanogenic potential.

25 12. Use according to claim 1 of a food composition for human consumption containing less than 1600 picomoles of polyamines to make a therapeutic food designed to combat tinnitus.

13. Use according to any one of the above claims, characterised in that the said composition contains less

than about 400 picomoles/g of putrescine, less than about 400 picomoles/g of spermidine, less than about 400 picomoles/g of spermine and less than about 400 picomoles/g of cadaverine.

5 14. Use according to claim 13, characterised in that the said composition contains less than about 400 and preferably less than about 200 picomoles/g of polyamines.

10 15. Use according to claim 14, characterised in that the said composition contains less than about 100, and preferably less than about 50 picomoles/g of putrescine, less than about 100 and preferably less than about 50 picomoles/g of spermidine, less than about 100 and preferably less than about 50 picomoles/g of spermine, and less than about 100 and preferably less than about 50
15 picomoles/g of cadaverine.

16. Use according to any one of the above claims, characterised in that the said composition includes 10 to 35% by dry weight of lipids, 8 to 30% of proteins, 35 to 80% of glucides, and up to 10% of a mix composed of
20 vitamins, minerals and electrolytes, as a percentage of the total dry weight.

17. Use according to claim 16, characterised in that the said composition is enriched with at least one inhibitor of intracellular synthesis of polyamines, with
25 a content by weight not exceeding 15% of the total dry weight of the composition.

18. Use according to claim 17, characterised in that the said composition is enriched with the said inhibitor

with a content by weight of between 0.2% and 7% of the total dry weight of the composition.

19. Use according to claim 18, characterised in that the said inhibitor is a competitive inhibitor of decarboxylase ornithine.

20. Use according to claim 19, characterised in that the said competitive inhibitor of the said composition is alpha-methylornithine.

21. Use according to any one of the above claims, characterised in that the said composition contains at least one antibiotic.

22. Use according to any one of the above claims, characterised in that the said composition is enriched with vitamins.

23. Use according to any one of claims 16 to 22, characterised in that the said glucides in the composition belong to the group comprising glucose polymers, maltodextrines, saccharose, modified starches, monohydrated glucose, dehydrated glucose syrup, glycerol monostearate and mixes of these products.

24. Use according to any one of claims 16 to 23, characterised in that the said proteins in the said composition belong to the group comprising milk soluble proteins, Soya proteins, serum peptides, powder egg yoke, potassium caseinate, non-phosphorylated peptides, casein peptides, mixed caseinate, soya isolate and mixes of these products.

25. Use according to any one of claims 16 to 24, characterised in that the said lipids in the said

composition belong to the group including butter oil, peanut oil, medium-chain triglycerides, grape seed oil, soya oil, onagra oil and mixes of these products.

26. Use according to any one of claims 16 to 25,
5 characterised in that the said lipids in the said composition are composed of a mix of at least one animal oil, at least one vegetable oil and glycerol stearate.

27. Use according to any one of the above claims,
characterised in that the said composition forms a daily
10 food ration for a human being and includes:

- between 75g and 500 g of glucides,
- between 20 g and 185 g of lipids,
- between 20 g and 225 g of proteins,
- sufficient quantities of vitamins, minerals and
15 electrolytes to satisfy the daily nutritional needs of a human being.

28. Use according to any one of the above claims,
characterised in that the said composition forms a daily
food ration for a human being and includes:

- 20 - less than 50 g and preferably between 1 and 10 g of the said inhibitor of intracellular synthesis of polyamines,
- between 75g and 500 g of glucides,
- between 20 g and 185 g of lipids,
- 25 - between 20 g and 225 g of proteins,
- sufficient quantities of vitamins, minerals and electrolytes to satisfy the daily nutritional needs of a human being.

29. Use according to any one of the above claims, characterised in that the said composition is a sub-multiple of a daily food ration for a human being and in that it includes:

- 5 - between $75/X$ g and $500/X$ g of glucides,
- between $20/X$ g and $185/X$ g of lipids,
- between $20/X$ g and $225/X$ g of proteins,
- sufficient quantities of vitamins, minerals and electrolytes to partially satisfy the daily nutritional
- 10 needs of a human being, and

X is an integer between 2 and 8 corresponding to the number of rations to be ingested by the patient to satisfy his daily nutritional needs.

- Use according to any one of the above claims,
- 15 characterised in that the said composition is a sub-multiple of a daily food ration for a human being and in that it includes:

- less than $50/X$ g and preferably $1/X$ to $10/X$ g of the said inhibitor of intracellular synthesis of
- 20 polyamines,

- between $75/X$ g and $500/X$ g of glucides,
- between $20/X$ g and $185/X$ g of lipids,
- between $20/X$ g and $225/X$ g of proteins,
- sufficient quantities of vitamins, minerals and
- 25 electrolytes to partially satisfy the daily nutritional needs of a human being, and

X is an integer between 2 and 8 corresponding to the number of rations to be ingested by the patient to satisfy his daily nutritional needs.

30. Use according to any one of the above claims, characterised in that the said composition is presented in dry form to be extemporaneously dissolved in a neutral vehicle.

5 31. Use according to any one of the above claims, characterised in that the said composition includes a neutral vehicle making it ready for use